Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: A randomized, 16-week, open-label study

Clinical Therapeutics

Volumn 33, Issue 11, 2011, Pages 1682-1693

  Farcasiu, Eugenia ^a   Ivanyi, Tibor ^b   Mozejko Pastewka, Barbara ^c   Birkus, Zita ^d   Csog, Jozsef ^d   Kowalska, Irina ^e   Coetzer, Thomas Frederic ^f   Bulgurlu, Sami ^g   Schinzel, Birgit ^h   Kiljanski, Jacek ^c  

^a NC Paulescu National Diabetes Nutrition and Metabolic Diseases Institute   (Romania)

^b ELI LILLY AND COMPANY   (United States)

^c Eli Lilly Polska Sp z oo   (Poland)

^d Karolina Hospital   (Hungary)

^e MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^f Clinresco Centres ^*  (South Africa)

^g GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^h ACCOVION GMBH   (Germany)

Author keywords

Metformin; Prandial premix therapy; Premixed insulin analogs; Type 2 diabetes

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN ASPART; INSULIN LISPRO; METFORMIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT GAIN;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; EATING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN LISPRO; MALE;

EID: 82855162717     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.001     Document Type: Article

References (40)

1. Defronzo R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
2. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203. American Diabetes Association and the European Association for Study of Diabetes.
3. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
4. Malone J.K., Bai S., Campaigne B.N., et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabetic Med 2005, 22:374-381.
5. Malone J.K., Kerr L.F., Campaigne B.N., et al. Combined therapy with insulin lispro Mix75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004, 26:2034-2044. Lispro Mixture-Glargine Study Group.
6. Raskin P., Allen E., Hollander P., et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005, 28:260-265. INITIATE Study Group.
7. Holman R.R., Thorne K.I., Farmer A.J., et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357:1716-1730. 4-T Study Group.
8. Buse J.B., Wolffenbuttel B.H., Herman W.H., et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009, 32:1007-1013.
9. Christiansen J.S., Liebl A., Davidson J.A., et al. Mid- and high-ratio premix insulin analogues: potential treatment options for patients with type 2 diabetes in need of greater postprandial blood glucose control. Diabetes Obes Metab 2010, 12:105-114.
10. Rosenstock J., Ahmann A.J., Colon G., et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008, 31:20-25.
11. Ligthelm R.J., Mouritzen U., Lynggaard H., et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006, 114:511-519.
12. Hermansen K., Colombo M., Storgaard H., et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002, 25:883-888.
13. Niskanen L., Jensen L.E., Raåstam J., et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004, 26:531-540.
14. Levit S., Toledano Y., Wainstein J. Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. Int J Clin Pract 2011, 65:165-171.
15. Temizel M., Mert M., Bozbey C., et al. Evaluation of the weight-increasing effects of biphasic analog and regular NPH insulin mixtures in patients with type 2 diabetes mellitus. J Diabetes 2010, 2:250-255.
16. Hirsch I.B., Bergenstal R.M., Parkin C.G., et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005, 23:78-86.
17. Roach, Koledova E., Metcalfe S., et al. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide. Clin Ther 2001, 23:1732-1744. Romania/Russia Mix25 Study Group.
18. Bretzel R.G., Arnolds S., Medding J., Linn T. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 2004, 27:1023-1027.
19. Kilo C., Mezitis N., Jain R., et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003, 17:307-313.
20. Garber A.J. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006, 66:31-49.
21. Douek I.F., Allen S.E., Ewings P., et al. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabet Med 2005, 22:634-640. Metformin Trial Group.
22. Liebl A., Jones S., Benroubi M., et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries. Curr Med Res Opin 2011, 27:887-895.
23. Garber A.J., Wahlen J., Wahl T., et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006, 8:58-66.
24. Schwartz S., Zagar A.J., Althouse S.K., et al. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus. Clin Ther 2006, 28:1649-1657.
25. Robbins D.C., Beisswenger P.J., Ceriello A., et al. Thrice-daily lispro mid mixture (MM) plus metformin (Met) improved glycemic control better than glargine (G) plus met in patients with type 2 diabetes (T2D). Diabetes 2006, 55:A132. Abstract.
26. Kazda C., Hülstrunk H., Helsberg K., et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006, 20:145-152.
27. Jacober S.J., Scism-Bacon J.L., Zagar A.J. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006, 8:448-455.
28. Dashora U., Ashwell S.G., Home P.D. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes. Diabetes Obes Metab 2009, 11:680-687.
29. Cucinotta D., Smirnova O., Christiansen J.S., et al. Three different premixed combinations of biphasic insulin aspart-comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes. Diabetes Obes Metab 2009, 11:700-708.
30. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.
31. Bretzel R.G., Nuber U., Landgraf W., et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008, 371:1073-1084.
32. Liebl A., Prager R., Binz K., et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009, 11:45-52. PREFER Study Group.
33. Cavalot F., Petrelli A., Traversa M., et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006, 91:813-819.
34. Esposito K., Ciotola M., Carleo D., et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab 2008, 93:1345-1350.
35. Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ 2006, 32:910-917.
36. Chan J.Y., Leyk M., Frier B.M., Tan M.H. Relationship between HbA1c and hypoglycaemia in patients with type 2 diabetes treated with different insulin regimens in combination with metformin. Diabetes Metab Res Rev 2009, 25:224-231.
37. Gao Y., Li G., Li Y., et al. Postprandial blood glucose response to a standard test meal in insulin-requiring patients with diabetes treated with insulin lispro mix 50 or human insulin mix 50. Int J Clin Pract 2008, 62:1344-1351.
38. Cryer P.E. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002, 45:937-948.
39. McCrimmon R.J., Frier B.M. Hypoglycaemia, the most feared complication of insulin therapy. Diabete Metab 1994, 20:503-512.
40. Riddle M.C., Rosenstock J., Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26:3080-3086. Insulin Glargine 4002 Study Investigators.